Author

Shiying Zhong

Institution: Lilly (China)

Observed institution: Lilly (China)

ORCID: 0000-0002-4425-5326

Observed ORCID: 0000-0002-4425-5326

OpenAlex ID: A5074860035

Real-World Treatment Patterns and Outcomes Among Patients with Episodic Migraine in China: Results from the Adelphi Migraine Disease Specific Programme™

2023 · Hongru Zhao, Zheman Xiao, et al. · Journal of Pain Research · 16

Real-World Analysis of Clinical Characteristics, Treatment Patterns, and Patient-Reported Outcomes of Insufficient Responders and Responders to Prescribed Acute Migraine Treatment in China

2023 · Lei Zhang, Diego Novick, et al. · Pain and Therapy · 7

Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial

2022 · Jiying Zhou, Guogang Luo, et al. · Advances in Therapy · 1

Works count: 3

Citation count: 24

H-index: 2

I10-index: 1